Elutia reports FY23 net loss $37.7M, cash $19.3M; CanGarooRM 510(k) decision expected H1 2024

ELUTIA INC.

Full year net sales $24.7M vs $23.8M; SimpliDerm up 38%, CanGaroo up 3.4%.
GAAP gross margin 45%; adjusted gross margin 58%; net loss $37.7M vs $32.9M.
Adjusted EBITDA loss improved to $14.6M from $22.9M.
Cash $19.3M as of Dec 31, 2023; proceeds $14.6M from orthobiologics divestiture.
FDA 510(k) decision for CanGarooRM expected in first half 2024; no additional data requested.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ELUTIA INC. reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

issued a press release announcing its results for the fourth quarter and full year ended December 31, 2023.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

ELUTIA INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-031918

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.